MedPath

Effect of Methyldopa on Uterine Artery Diameter in Pregnant Women With Mild Preeclampsia

Phase 2
Completed
Conditions
Pregnant Women With Mild Preeclampsia
Interventions
Drug: Placebo
Registration Number
NCT01674127
Lead Sponsor
Isfahan University of Medical Sciences
Brief Summary

The present study examined the effects of Methyldopa on uterine artery diameter, uterine artery blood flow, umbilical artery and fetal middle-cerebral artery in patients with Preeclampsia, using Doppler ultrasound.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
MethyldopaMethyldopaIn case group, 25 patients, under treatment, using Methyldopa for 7 days, received 500 mgs of Methyldopa in its oral form per day and in control group, participants received placebo for 7 days.
placeboPlacebo-
Primary Outcome Measures
NameTimeMethod
Doppler indices7 days

In case group, 25 patients, under treatment, using Methyldopa for 7 days, received 500 mgs of Methyldopa in its oral form per day and in control group, participants received placebo for 7 days.Before and after drug use, Doppler ultrasound test was done by a radiology specialist not informed of patients grouping. Also, pulsatility index, resistance index, systolic/diastolic blood flow ratios of uterine artery, umbilical artery and middle-cerebral artery were evaluated. Registered for all patients, age, BMI, gestational week and the number of pregnancies were among other examined variables.

Doppler indices of examined arteries in studied groups were evaluated by color Doppler ultrasound of model "Hitachi 3/6 MHz".

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath